Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
New supplementary Strangvac study demonstrates immunological memory with long duration
The Swedish biotechnology company Intervacc has now taken another step towards confirming the effect of its vaccine, one of the company’s development development projects, against the infamous streptococcal infection strangles in the horse. A new supplementary...Intervacc recieves funding from Eurostars for further development of vaccine for piglets.
Intervacc has been awarded funding through the Eurostars-2 program for further development of a vaccine against severe infection of piglets caused by Streptococcus suis. The Eurostars-2 program, a part of EU:s Horizon 2020, thus finances approximately 50% of the...Intervacc signs an agreement for future filling and release of Strangvac.
Strangvac® is Intervacc’s vaccine against strangles, which is a very severe and contagious infection in the horse. Intervacc has previously signed an agreement with 3P Biopharmaceuticals in Pamplona, Spain for large-scale commercial production of the components...Intervacc AB – Nomination Committee’s proposal for Board of Directors for the 2018 Annual General Meeting.
The Nomination Committee hereby announces its proposal regarding the Chairman of the Board of Directors and other Board members to the Annual General Meeting of Intervacc AB (publ) on June 14th, 2018. The Nomination Committee proposes: that the Board of Directors...Intervacc completes manufacturing agreement for new vaccine against equine strangles
Nyhetstjänster
